%0 Journal Article
%T A case study of personalized therapy for osteosarcoma.
%A Davis LE
%A Hofmann NE
%A Li G
%A Huang ET
%A Loriaux MM
%A Bracha S
%A Helfand SC
%A Mata JE
%A Marley K
%A Mansoor A
%A Tyner JW
%A Abraham J
%A Séguin B
%A Keller C
%J Pediatr Blood Cancer
%V 60
%N 8
%D Aug 2013
%M 23526721
%F 3.838
%R 10.1002/pbc.24512
%X <B>BACKGROUND: </B>Effective targeted therapies are needed in sarcomas, but the biological heterogeneity of these tumors has presented a challenge to clinical integration of small molecule inhibitors in sarcoma treatment. Here we outline a process to personalize therapy for sarcomas through a case study of a canine with spontaneous osteosarcoma.<BR><B>METHODS: </B>Rapid establishment of a primary tumor cell culture is described, followed by efficient functional characterization of the tumor that identified the Src inhibitor dasatinib as the most effective targeted therapy for this individual dog.<BR><B>RESULTS: </B>Adjuvant dasatinib was administered for a total of 26 weeks following treatment with chemotherapy. Pharmacokinetic studies confirm that a therapeutic serum concentration was achieved at a tolerable dose of 0.75 mg/kg/day. The canine patient remains without evidence of recurrent disease 24 months following initial diagnosis.<BR><B>CONCLUSIONS: </B>The approach described through this illustrative case study is broadly applicable and might be used for other solid tumors in canines as well as in humans.